Scarica l'app Stockscreener
0.00
100.00%
-63.48
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTLT Giù?
Forum
Previsione
Catalent Inc Borsa (CTLT) Ultime notizie
Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma
CRDMO Market Research 2025: A Highly Competitive $328 Billion Market by 2029 with Lonza Group, WuXi, Catalent, Sai Life Sciences, Syngene, Jubilant Biosys, and Thermo Fisher Scientific Leading - Yahoo Finance
Unit Dose Manufacturing Industry Report 2025-2030: Market to Cross $150.6 Billion Led by Catalent, Unither Pharmaceuticals, and Thermo Fisher Scientific - Yahoo Finance
Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Catalent, Inc. (CTLT) Investigation - ACCESS Newswire
Healthcare CMO Market Projected To Witness Substantial Growth, 2025-2032: Lonza Group, Catalent, Inc., Aenova - EIN News
Per-Encounter Medical Market to Witness Remarkable Growth with Catalent Inc., Smiths Medical Inc., Cardinal Health - openPR
Catalent announces new board appointments - ROI-NJ.com
Catalent Appoints Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors - citybiz
Catalent Announces New Board Appointments - Business Wire
Novo to grow Catalent? Rumor mill spins amid Trump tariff threat - BioProcess Insider
Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN
Ardena Acquires Catalent’s Drug Product Manufacturing Facility in Somerset, NJ - Contract Pharma
Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America - Yahoo Finance
Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com
Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma
Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times
Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire
Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan
How Novo’s Acquisition Of Catalent Cleared European Regulators - Citeline
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards? - MSN
Catalent (NYSE:CTLT) Now Covered by StockNews.com - Defense World
Pace Life Sciences Expands Capacity and Capability With Acquisition of Catalent’s Analytical Services Laboratory in Research Triangle Park - ACCESS Newswire
Catalent's Award-Winning Innovations and Community Engagement Initiatives - Pharmaceutical Technology
Catalent to make CAR-T for Galapagos; Kindeva gets $129M for nerve agent antidote - Endpoints News
Catalent backs decentralised manufacture of Galapagos’ CAR-T therapy - MSN
Catalent to further expand Galapagos’ decentralized CAR-T manufacturing network in US - Indian Pharma Post
Catalent to support Galapagos’ decentralized cell therapy approach - The Pharma Letter
Catalent to Support Galapagos’ Decentralized CAR-T Therapy Trials - Contract Pharma
Catalent, Inc. (NYSE:CTLT) Given Average Rating of “Hold” by Analysts - Defense World
StockNews.com Begins Coverage on Catalent (NYSE:CTLT) - Defense World
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus - Yahoo Finance
JPM 2025: Thermo Fisher ‘very positive’ on sterile demand as Catalent takes capacity out of market - Pharmaceutical Technology
Catalent (NYSE:CTLT) Now Covered by Analysts at StockNews.com - Defense World
Novo Holdings completes purchase of Catalent - MSN
Catalent, Inc. Share Price Target ‘$63.40’, now -.1% Downside Potential - DirectorsTalk Interviews
Catalent (NYSE:CTLT) Coverage Initiated by Analysts at StockNews.com - Defense World
JPMorgan Chase & Co. Acquires 199,427 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty - MSN
Judge Partially Dismisses Investor Suit Against Google Over Ad Practices - PYMNTS.com
Principal Financial Group Inc. Has $12.61 Million Position in Catalent, Inc. (NYSE:CTLT) - Defense World
Catalent, Inc. (NYSE:CTLT) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Five Private Equity Deals That Helped Fuel Big Law in 2024 (1) - Bloomberg Law News
Siren Biotechnology, Catalent Partner for Manufacturing of AAV Gene Therapies - Contract Pharma
Catalent Announces $12 Million Expansion Program at Kansas City Facility - Contract Pharma
Staff AccountantCatalent, Inc. - Built In
Novo Nordisk Set to Close Catalent Deal Without FTC Challenge - MSN
Novo Holdings completes $16.5 billion takeover of Catalent - MSN
Skadden, Goodwin, Davis Polk act as Novo closes $16.5bn Catalent deal - The Global Legal Post
Novo Holdings says its acquisition of Catalent is complete. - The Herald-Times
Novo Holdings Strengthens Pharma Standing With Catalent Acquisition - Finimize
1.22%
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):